Munich - Delayed Quote EUR

AnaptysBio Inc (AN6.MU)

15.60

0.00

(0.00%)

At close: April 16 at 8:00:12 AM GMT+2

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 22 days ago

ANAB

MGTX
Anaptys Announces Stock Repurchase Plan

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticip

GlobeNewswire 23 days ago

ANAB
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market rebounded from a turbulent week, fueled by easing fears of a government shutdown and renewed confidence in the U.S. economy. Fresh February data signaled that inflation was cooling in line with the Federal Reserve’s targets, helping to calm concerns about economic strain. Looking at the bigger picture, Wells Fargo’s senior global market strategist Scott Wren sees plenty of

TipRanks last month

ANAB

ANNX
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ANAB
Anaptys Announces Participation in March Investor Conferences

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate

GlobeNewswire last month

ANAB
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and translational data for rosnilimab in RA in Q2 2025Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulatorAnnounced excl

GlobeNewswire last month

ANAB
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS-28 CRP and key secondary endpoints were met. However, efficacy was numerically undifferentiated from peresolimab and the firm says rosnilimab “looks like a me-too in RA.” Confusion and questions around handing of the placebo group post double-blinded study period through week 12 raises questions about the

TipRanks 2 months ago

ANAB
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks 2 months ago

ANAB

ATRC
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 2 months ago

ANAB
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

AnaptysBio’s trial saw 69% of patients treated with rosnilimab achieve low disease activity by week 12.

Clinical Trials Arena 2 months ago

ANAB

GLDAF
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

Investor's Business Daily 2 months ago

ANAB
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDADemonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially

GlobeNewswire 2 months ago

ANAB
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT. A live webcast of the call will be avai

GlobeNewswire 2 months ago

ANAB
Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But that...

Simply Wall St. 2 months ago

ANAB
Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Vanda will pay AnaptysBio $10m upfront along with $5m for the current drug supply.

Pharmaceutical Technology 2 months ago

VNDA

ANAB
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT. A live webcast of the presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/

GlobeNewswire 2 months ago

ANAB
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to receive $15 million from Vanda, comprised of a $10 million upfront payment and $5 million for existing drug supplyAnaptys to receive a 10% royalty on global net sales of imsidolimab WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys

GlobeNewswire 2 months ago

VNDA

ANAB
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

Zacks 2 months ago

ANAB

INSP
How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

AnaptysBio (ANAB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks 3 months ago

ANAB
Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

Zacks 3 months ago

UTHR

ANAB

Performance Overview

Return	AN6.MU	S&P 500 (^GSPC)
YTD	+23.81%	-10.30%
1-Year	-22.77%	+4.44%
3-Year	-30.36%	+20.10%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AnaptysBio Inc (AN6.MU)

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

Anaptys Announces Stock Repurchase Plan

Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago

Vanda and AnaptysBio link for generalised pustular psoriasis therapy

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?

How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Performance Overview